MA32130B1 - Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2 - Google Patents

Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2

Info

Publication number
MA32130B1
MA32130B1 MA33135A MA33135A MA32130B1 MA 32130 B1 MA32130 B1 MA 32130B1 MA 33135 A MA33135 A MA 33135A MA 33135 A MA33135 A MA 33135A MA 32130 B1 MA32130 B1 MA 32130B1
Authority
MA
Morocco
Prior art keywords
maslinic acid
treatment
cox
pathologies
symptoms
Prior art date
Application number
MA33135A
Other languages
Arabic (ar)
English (en)
Inventor
Osuna José Prados
López De Hierro Andrés García-Granados
Sánchez Andrés Parra
Rodríguez Antonio Martínez
Original Assignee
Biomaslinic S L
Univ Granada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomaslinic S L, Univ Granada filed Critical Biomaslinic S L
Publication of MA32130B1 publication Critical patent/MA32130B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation de l'acide maslinique ou de mélanges naturels, synthétiques ou semi-synthétiques riches en acide maslinique ou d'une composition contenant de l'acide maslinique dans le traitement de pathologies associées à l'activation de cox-2. L'invention est destinée, entre autres, au traitement symptomatique et/ou régénératif de l'arthrose, de l'arthrite rhumatoïde, des fibromyalgies, de la sciatique et d'autres troubles articulaires au diagnostic malaisé. L'invention porte aussi sur l'administration par voie topique de l'acide maslinique, des mélanges et de la composition précités.
MA33135A 2008-04-03 2010-08-31 Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2 MA32130B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200801069A ES2328999B1 (es) 2008-04-03 2008-04-03 Uso del acido maslinico para el tratamiento de patologias y sus sintomas mediante la inhibicion de cox-2.
PCT/ES2009/000195 WO2009121992A2 (fr) 2008-04-03 2009-04-03 Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2

Publications (1)

Publication Number Publication Date
MA32130B1 true MA32130B1 (fr) 2011-03-01

Family

ID=41135978

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33135A MA32130B1 (fr) 2008-04-03 2010-08-31 Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2

Country Status (9)

Country Link
US (1) US20110105611A1 (fr)
EP (1) EP2258374A4 (fr)
JP (1) JP2011516457A (fr)
CN (1) CN102014922A (fr)
ES (1) ES2328999B1 (fr)
MA (1) MA32130B1 (fr)
MX (1) MX2010009467A (fr)
RU (1) RU2010135252A (fr)
WO (1) WO2009121992A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102210691B (zh) * 2010-04-01 2013-04-10 华东师范大学 山楂酸及其衍生物在制备抑制破骨细胞分化和功能的治疗和/或预防药物中的应用
CN102558278B (zh) * 2010-12-28 2014-07-09 复旦大学 三萜类化合物及其在制备抗补体药物中的用途
KR101485748B1 (ko) 2012-02-06 2015-01-22 윌리엄 엘. 프리드젠 팜시클로비어 및 셀레콕시브를 포함한, 기능성 신체 증후군에 대한 항바이러스 화합물 및 cox-2 억제제 조합 치료법
JP6547183B2 (ja) * 2015-03-16 2019-07-24 日本製粉株式会社 トリテルペンを有効成分として含有する変形性関節症の予防又は治療の為の組成物
JP2017109942A (ja) * 2015-12-15 2017-06-22 日本製粉株式会社 オレアナン型トリテルペンを有効成分として含有するトレーニング機器を使用しないレジスタンストレーニングによる膝関節機能改善作用および骨格筋機能増強作用を促進させる為の組成物
CN106420765A (zh) * 2016-09-10 2017-02-22 浙江大学 山楂酸在制备治疗和预防中枢神经系统疾病药物中的用途
JP2019043876A (ja) * 2017-08-31 2019-03-22 日本製粉株式会社 マスリン酸を有効成分として含有するタンパク質合成促進剤及び骨格筋肥大促進剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001072265A1 (fr) 2000-03-31 2001-10-04 The Nisshin Oil Mills, Ltd. Preparation externe pour la peau et agents d'embellissement
EP1321145A4 (fr) 2000-07-31 2006-03-22 Nisshin Oillio Ltd Agents antitumoraux
JPWO2002052956A1 (ja) 2000-12-27 2004-04-30 日清オイリオ株式会社 抗腫瘍用飲食物
JPWO2002078468A1 (ja) 2001-03-30 2004-08-19 日清オイリオ株式会社 血管障害疾患用飲食物
WO2003011267A1 (fr) 2001-07-31 2003-02-13 The Nisshin Oillio, Ltd. Medicaments anti-obesite et ses substances
EP1431379A4 (fr) * 2001-09-28 2005-08-31 Nisshin Oillio Ltd Procede de production de compositions de matiere grasse renfermant de l'acide oleanolique et/ou de l'acide maslinique
WO2003039270A1 (fr) 2001-11-08 2003-05-15 The Nisshin Oillio,Ltd. Aliments et boissons agissant contre l'obesite
WO2003057224A1 (fr) * 2001-12-28 2003-07-17 The Nisshin Oillio, Ltd. Inducteur d'apoptose
ES2267403B1 (es) * 2005-08-17 2008-03-16 Universidad De Granada Composicion nutraceutica obtenida de triterpenos naturales de la olea europaea.

Also Published As

Publication number Publication date
CN102014922A (zh) 2011-04-13
EP2258374A2 (fr) 2010-12-08
WO2009121992A2 (fr) 2009-10-08
JP2011516457A (ja) 2011-05-26
ES2328999A1 (es) 2009-11-19
US20110105611A1 (en) 2011-05-05
EP2258374A4 (fr) 2012-07-25
MX2010009467A (es) 2010-12-20
RU2010135252A (ru) 2012-05-10
ES2328999B1 (es) 2010-10-27
WO2009121992A3 (fr) 2010-01-07

Similar Documents

Publication Publication Date Title
MA32130B1 (fr) Utilisation de l'acide maslinique dans le traitement de pathologies et de leurs symptômes par inhibition de cox-2
MA37808A1 (fr) Composés et leurs utilisations thérapeutiques
MA31845B1 (fr) Pipéridino-dihydrothiénopyrimidines substituées
BRPI0710485B8 (pt) composições líquidas úteis no tratamento de doenças respiratórias
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
MA31983B1 (fr) Dérivés d'acide phosphonique et leur utilisation en tant qu'antagonistes du récepteur p2y12
MA33920B1 (fr) Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
MA48486B1 (fr) Polymères liant les protons pour administration orale
MA34474B1 (fr) Agonistes de gpr40
MA28140A1 (fr) Compositions et formes dosifiees pour favoriser l'absorption de la gabapentine et de la pregabaline
MA34225B1 (fr) Préparation stable de mia/cd-rap
MA32798B1 (fr) Acides naphtylacétiques
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
TNSN00139A1 (fr) Acides phenoxyacetiques substitues
MA33758B1 (fr) Polypeptides anti-tnfr1 stables, domaines variables de l'anticorps, et antagonistes
FR2913885B1 (fr) Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines
FR2930552B1 (fr) N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
Bansode et al. Salivary biomarkers of dental caries-A review article
BR112012008843A2 (pt) Composto, composição farmacêutica, uso do composto, e. mistura
MA38016A1 (fr) Composition injectable stable contenant du diclofénac et du thiocolchicoside
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA32012B1 (fr) Octahydroquinolizines destinees au traitement du diabete
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
Silveira et al. Hereditary sensory and autonomic neuropathy type 3 in non-Jewish child
Touyz Periodontitis contributes to initiation, progress and aggravation of septic shock; a feasible hypothesis